home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences
Search  -  prev / next
 
 

Drug Development in a Post-COVID Era

 
  July 16, 2021  
     
 
Xtalks, Online
2021-08-25


Drug discovery and development pipelines have been greatly impacted by COVID – some more than others. Technology innovation, remote workforces, decentralized clinical trials and faster drug approval (think of COVID vaccines) have all been on the rise. All the while adhering to rigid regulatory frameworks and maintaining good data management practices.

This certainly makes for a very competitive biotech funding space. We are expected to have more IPOs in 2021 than the record-setting 81 in 2020*, which begs the question: what is in store for drug discovery in the next ten years?

Register for this webinar to hear John Keilty, Venture Partner from Third Rock Ventures and Alok Tayi, PhD, VP of Life Sciences at Egnyte discuss the recent biotechnology trends. They will provide insights and real-world actions that can be taken now to keep pace.

 
 
Organized by: Xtalks
Invited Speakers:

Alok Tayi, PhD, Vice President of Life Sciences, Egnyte

John Keilty, Venture Partner, Third Rock Ventures

 

 
Deadline for Abstracts: -
 
Registration: Register at Xtalks.
E-mail: jozeph@xtalks.com
 
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.